Oxybutynin immediate release
Showing 1 - 25 of 9,513
Heat Effect Trial in Baltimore (oxybutynin)
Completed
- Heat Effect
-
Baltimore, MarylandGeneral Clinical Research Center (GCRC) at the University of Mar
Mar 14, 2022
Healthy Participants Trial in Ruddington (ALXN2050 MR Prototype Tablet, ALXN2050 Immediate Release (IR) Tablet, ALXN2050 MR
Not yet recruiting
- Healthy Participants
- ALXN2050 MR Prototype Tablet
- +2 more
-
Ruddington, Nottinghamshire, United KingdomQuotient Science Ltd
Mar 13, 2023
Healthy Volunteers Trial (BMS-986419 DR Capsule, BMS-986419 IR Tablet)
Not yet recruiting
- Healthy Volunteers
- BMS-986419 DR Capsule
- BMS-986419 IR Tablet
- (no location specified)
Jul 20, 2023
Atopic Dermatitis Trial in Hangzhou (TLL-018 extended-release tablet, TLL-018 immediate-release tablet)
Active, not recruiting
- Atopic Dermatitis
- TLL-018 extended-release tablet
- TLL-018 immediate-release tablet
-
Hangzhou, Zhejiang, ChinaThe Second Affiliated Hospital Zhejiang University School of Med
Jul 12, 2023
Healthy Trial in Porto (Dynamic foam rolling)
Recruiting
- Healthy
- Dynamic foam rolling
-
Porto, Portugal
- +1 more
Feb 10, 2023
Flat Foot Trial in Istanbul (Graston, Percussive massage)
Completed
- Flat Foot
- Graston
- Percussive massage
-
Istanbul, Turkeyİstanbul Gelisim University
Sep 14, 2023
Tension-Type Headache Trial in Rawalpindi (sustained natural apophyseal glides (SNAGS), suboccipital muscle release,
Active, not recruiting
- Tension-Type Headache
- sustained natural apophyseal glides (SNAGS)
- +2 more
-
Rawalpindi, Punjab, PakistanFauji Foundation Hospital
May 22, 2023
N/A Healthy Individuals Trial (Myofascial Release, Light Touch Contact)
Not yet recruiting
- N/A Healthy Individuals
- Myofascial Release
- Light Touch Contact
- (no location specified)
Jun 21, 2023
Healthy Participants Trial in Overland Park (Treatment A: Emraclidine 30mg IR tablets (reference), Treatment B: Emraclidine 30mg
Not yet recruiting
- Healthy Participants
- Treatment A: Emraclidine 30mg IR tablets (reference)
- +3 more
-
Overland Park, KansasOverland Park, Kansas
Jun 28, 2023
Neuropathic Pain, Diabetes, Type 2 Trial in Korea, Republic of (pregabalin sustained release tablet, pregabalin immediate
Active, not recruiting
- Neuropathic Pain
- Diabetes Mellitus, Type 2
- pregabalin sustained release tablet
- pregabalin immediate release capsule
-
Cheongju, Chungcheongbuk-do, Korea, Republic of
- +7 more
Nov 14, 2022
Myofascial Spasm Trial in Istanbul (Self myofascial Release, myofascial release)
Not yet recruiting
- Myofascial Spasm
- Self myofascial Release
- myofascial release
-
Istanbul, Maltepe, Turkey
- +2 more
Apr 6, 2023
Hamstring Injury, Masseter, Myofascial Release Trial in Ankara (Static stretching, Myofascial Release)
Recruiting
- Hamstring Injury
- +5 more
- Static stretching
- Myofascial Release
-
Ankara, Keçiören, TurkeyCaglar Soylu
Jan 26, 2023
Healthy Volunteer Trial in Grayslake (ABBV-903 Tablet Form 1, ABBV-903 Tablet Form 2)
Recruiting
- Healthy Volunteer
- ABBV-903 Tablet Form 1
- ABBV-903 Tablet Form 2
-
Grayslake, IllinoisAcpru /Id# 254926
Apr 20, 2023
Lateral Epicondylitis Trial in Lahore (mulligan mobilization, myofascial release)
Completed
- Lateral Epicondylitis
- mulligan mobilization
- myofascial release
-
Lahore, Punjab, PakistanSumra Riaz
Oct 1, 2022
Abuse Potential Trial in Overland Park (Placebo, Alprazolam 2 mg, Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg)
Completed
- Abuse Potential
- Placebo
- +4 more
-
Overland Park, KansasAltasciences Clinical Kansas
Oct 19, 2023
Bladder Cancer Trial in Melbourne (APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending
Not yet recruiting
- Bladder Cancer
- APL-1202 and APL-1501 (Single ascending dose)
- APL-1202 and APL-1501 (Multiple Ascending dose)
-
Melbourne, Victoria, AustraliaNucleus Network Pty Ltd
Sep 11, 2023
Recreational Drug Use Trial in Overland Park (PF614, Oxycodone Hydrochloride 40 mg, Placebo)
Completed
- Recreational Drug Use
- PF614
- +2 more
-
Overland Park, KansasDr. Vince Clinical Research
Jan 3, 2023
Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome Trial (Guanfacine Hydrochloride
Not yet recruiting
- Hyperactivity in Children With Down Syndrome
- Impulsivity in Children With Down Syndrome
- Guanfacine Hydrochloride Immediate Release
- Placebo
- (no location specified)
Sep 18, 2023
Healthy Trial in Nottingham (BLU-5937 IR, BLU-5937 ER)
Recruiting
- Healthy
- BLU-5937 IR
- BLU-5937 ER
-
Nottingham, England, United KingdomQuotient Sciences
Oct 4, 2022
Safety Issues, Pharmacokinetic Trial in Kiel (controlled-ileocolonic-release nicotinamide (SAD/MAD/MD), Immediate-release
Recruiting
- Safety Issues
- Pharmacokinetic
- controlled-ileocolonic-release nicotinamide (SAD/MAD/MD)
- +3 more
-
Kiel, GermanyUniversity Medical Center Schleswig-Holstein
Feb 16, 2022
Bioequivalence Trial in Lenexa (Pharmaceutical-lipid aspirin (PL-ASA))
Completed
- Bioequivalence
- Pharmaceutical-lipid aspirin (PL-ASA)
-
Lenexa, KansasPRA-EDS
Apr 20, 2022